Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics.
Click here to listen to Dr. Santos, FLASCO Secretary, discuss the role of liquid biopsy in NSCLC. Dr. Santos shares his experience using Guardant360 in clinical practice, including his perspective on the following questions:
- What is the biggest problem you see as a thoracic oncologist with regards to genotyping and patients receiving appropriate therapies?
- How does Guardant360 help you overcome some of these problems?
- What is your greatest patient success story utilizing Guardant360?
- What do you think is the biggest misconception about liquid biopsies and Guardant360?
To learn more visit www.Guardant360.com, and to learn about FDA approved Guardant360® CDx for genomic profiling across all solid tumors and as a companion diagnostic for patients who are eligible for treatment with osimertinib, visit www.Guardant360CDx.com.